Equities research analysts expect Aptevo Therapeutics Inc (NASDAQ:APVO) to report earnings per share of ($0.57) for the current quarter, Zacks reports. Two analysts have made estimates for Aptevo Therapeutics’ earnings. The highest EPS estimate is ($0.53) and the lowest is ($0.60). The business is scheduled to report its next quarterly earnings results on Tuesday, March 12th.
According to Zacks, analysts expect that Aptevo Therapeutics will report full-year earnings of ($2.31) per share for the current fiscal year, with EPS estimates ranging from ($2.37) to ($2.27). For the next year, analysts anticipate that the firm will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.71) to ($1.71). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Aptevo Therapeutics.
Aptevo Therapeutics (NASDAQ:APVO) last posted its earnings results on Wednesday, November 14th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.01. Aptevo Therapeutics had a negative return on equity of 78.85% and a negative net margin of 252.44%. The business had revenue of $5.82 million during the quarter, compared to the consensus estimate of $6.87 million.
Shares of Aptevo Therapeutics stock traded up $0.04 on Tuesday, hitting $1.61. The stock had a trading volume of 69,910 shares, compared to its average volume of 122,560. Aptevo Therapeutics has a 52-week low of $1.11 and a 52-week high of $6.35. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.91 and a quick ratio of 3.65.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Sessa Capital IM L.P. raised its stake in Aptevo Therapeutics by 35.9% during the 3rd quarter. Sessa Capital IM L.P. now owns 706,613 shares of the biotechnology company’s stock valued at $3,590,000 after acquiring an additional 186,719 shares during the last quarter. Renaissance Technologies LLC raised its stake in Aptevo Therapeutics by 11.1% during the 3rd quarter. Renaissance Technologies LLC now owns 1,277,100 shares of the biotechnology company’s stock valued at $6,488,000 after acquiring an additional 127,700 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Aptevo Therapeutics by 5.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,425,567 shares of the biotechnology company’s stock valued at $7,242,000 after acquiring an additional 73,911 shares during the last quarter. Acadian Asset Management LLC raised its stake in Aptevo Therapeutics by 20.2% during the 3rd quarter. Acadian Asset Management LLC now owns 441,765 shares of the biotechnology company’s stock valued at $2,244,000 after acquiring an additional 74,256 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Aptevo Therapeutics by 21.2% during the 2nd quarter. Northern Trust Corp now owns 70,416 shares of the biotechnology company’s stock valued at $352,000 after acquiring an additional 12,299 shares during the last quarter. 32.59% of the stock is owned by hedge funds and other institutional investors.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
See Also: Initial Public Offering (IPO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.